Veloxis Pharmaceuticals A/S moves Danish activates to the U.S.
“As most of the company's activities are located in the U.S. combined with the launch of Envarsus® XR in the US through our own sales force we believe a consolidation of activities will further strengthen the company to meet new opportunities and to further grow our business.” said Craig Collard, CEO.
Veloxis will continue to be a Danish company listed on Nasdaq Copenhagen A/S.
The information provided in this announcement does not change Veloxis' financial guidance for the 2015 financial year.
For more information, please contact:
Craig A. Collard
President & CEO
Phone: +1 919 524 4317
Email: cac@veloxis.com
Veloxis Pharmaceuticals A/S (VELO)
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.